This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Neurology

Pain

Lipocalin (LCN2; NGAL)

In vitro and mouse studies suggest inhibiting LCN2 could help treat neuropathic pain. In mouse cortical neurons, Lcn2 increased expression of pain-associated chemokines compared with denatured Lcn2. In normal mice, Lcn2 increased sensitivity to mechanical pain compared with vehicle. In a mouse model of peripheral nerve injury, Lcn2-deficient animals had lower expression of pain-associated chemokines in the spinal cord and less sensitivity to mechanical pain than wild-type controls. Ongoing work includes investigating the role of Lcn2 in models of chronic inflammatory pain.

SciBX 6(32); doi:10.1038/scibx.2013.869
Published online Aug. 22, 2013

Patented by Kyungpook National University; unlicensed

Jeon, S. et al. J. Biol. Chem.; published online July 8, 2013;
doi:10.1074/jbc.M113.454140
Contact: Kyoungho Suk, Kyungpook National University School of Medicine, Daegu, South Korea
e-mail:
ksuk@knu.ac.kr